Sex Differences In The Evolution Of Neutralizing Antibodies To SARS-CoV-2

This study aims to determine the differences in the evolution of the immune response in the months following SARS-CoV-2 infection in men and women

Keywords: SARS-CoV-2; antibodies; sex-related differences; COVID-19.

Description of the Study:

  • Title: Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2.
  • Principal Investigators: Ludivine Grzelak, Aurélie Velay, Yoann Madec, Floriane Gallais, Isabelle Staropoli, Catherine Schmidt-Mutter, Marie-Josée Wendling, Nicolas Meyer, Cyril Planchais, David Rey, Hugo Mouquet, Nathalie Reix, Ludovic Glady, Yves Hansmann, Timothée Bruel, Jérome De Sèze, Arnaud Fontanet, Maria Gonzalez, Olivier Schwartz and Samira Fafi-Kremer.
  • Centres of Implementation: Strasbourg University Hospital, France.
  • Study Population: 308 RT-qPCR+ healthcare workers with mild disease.
  • Study Type: Prospective, interventional, single-centre, longitudinal cohort study.
  • Design: Antibodies against SARS (S), nucleoprotein (N) and neutralising antibodies (NAbs) were measured in participants’ sera, collected at two time points up to 6 months after symptom onset.
  • Methods:
    – Statistical analysis
    – Serological assays

Objectives of the Study:

Principal Objective: To study the evolution of the immune response in the months following SARS-CoV-2 infection in men and women.

More about this Study:

Scientific Context: The duration of humoral immune responses to SARS-CoV-2 is a matter of debate. Patients with severe COVID-19 produce more antibodies than asymptomatic or mildly symptomatic individuals. Some studies showed a rapid decline in convalescents, regardless of disease severity, while others reported stable antibody titres in the first three months.

Anti-Spike (S) antibody amounts correlate with neutralising capacity, as S is the main, if not the only, target of neutralising antibodies. Neutralising antibody levels also vary according to the time since symptom onset (POS) and the severity of the disease. Little is known about the influence of sex, age and body mass index (BMI) on the longevity of anti-SARS-CoV-2 antibodies, especially in mildly symptomatic individuals, who represent the majority of COVID-19 cases.

Other Studies About Immunology:

Autoantibodies As An Indicator Of Poor Prognosis In COVID-19

This study shows that 10% of patients with severe COVID-19 have neutralising antibodies against the cytokine interferon type 1.

Prognostic Implications Of Neutrophil-Lymphocyte Ratio In COVID-19

This study aims to determine whether the neutrophil-to-lymphocyte ratio (NLR) can be useful in the diagnosis and treatment of COVID-19.

Risk Score For Predicting In-hospital Mortality In COVID-19

The RIM score, a simple and widely available tool that can help identify patients at risk of fatal COVID-19 outcomes.


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

Autoimmune and immune-mediated diseases and symptomatic COVID-19

This study analyses if patients with autoimmune diseases and coronavirus infection have a lower risk of developing severe COVID.


Are you immunosuppressed? Engage this study and help underestand the kinetics of adaptive immunization against COVID-19.

Developing Therapies Based On The SARS-CoV-2 Cellular Response

This study aims to better understand the functioning of the immune response to SARS CoV-2 in order to propose new treatments based on the body’s cellular response to COVID-19.